Ibrutinib is an important drug used in the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Its development has significantly improved survival rates for patients facing these diseases.
The manufacturer of ibrutinib is a leading pharmaceutical company known for its commitment to developing innovative cancer treatments that improve patient outcomes.